Q2 2024 EPS Estimates for Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Decreased by Analyst

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHMFree Report) – Research analysts at Leerink Partnrs cut their Q2 2024 EPS estimates for shares of Reneo Pharmaceuticals in a note issued to investors on Tuesday, May 7th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will earn ($0.22) per share for the quarter, down from their previous forecast of ($0.16). The consensus estimate for Reneo Pharmaceuticals’ current full-year earnings is ($0.85) per share. Leerink Partnrs also issued estimates for Reneo Pharmaceuticals’ Q3 2024 earnings at ($0.19) EPS, Q4 2024 earnings at ($0.17) EPS, FY2024 earnings at ($0.82) EPS and FY2025 earnings at ($0.69) EPS.

Reneo Pharmaceuticals Stock Down 2.7 %

Shares of RPHM opened at $1.81 on Friday. The stock has a market capitalization of $60.49 million, a P/E ratio of -0.72 and a beta of 0.22. The firm has a fifty day simple moving average of $1.68 and a two-hundred day simple moving average of $3.05. Reneo Pharmaceuticals has a twelve month low of $0.98 and a twelve month high of $9.45.

Reneo Pharmaceuticals (NASDAQ:RPHMGet Free Report) last announced its quarterly earnings results on Thursday, March 28th. The company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.15).

Institutional Investors Weigh In On Reneo Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Dorsey Wright & Associates bought a new stake in shares of Reneo Pharmaceuticals during the 3rd quarter valued at about $28,000. Bank of New York Mellon Corp boosted its position in Reneo Pharmaceuticals by 13.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 35,963 shares of the company’s stock valued at $274,000 after acquiring an additional 4,165 shares in the last quarter. Barclays PLC grew its holdings in shares of Reneo Pharmaceuticals by 5.7% during the 3rd quarter. Barclays PLC now owns 78,118 shares of the company’s stock worth $595,000 after acquiring an additional 4,244 shares during the period. Pale Fire Capital SE bought a new position in shares of Reneo Pharmaceuticals in the 3rd quarter worth approximately $113,000. Finally, SG Americas Securities LLC purchased a new position in shares of Reneo Pharmaceuticals in the 4th quarter valued at approximately $35,000. Hedge funds and other institutional investors own 90.98% of the company’s stock.

Reneo Pharmaceuticals Company Profile

(Get Free Report)

Reneo Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.

Recommended Stories

Earnings History and Estimates for Reneo Pharmaceuticals (NASDAQ:RPHM)

Receive News & Ratings for Reneo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reneo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.